119 related articles for article (PubMed ID: 32763003)
41. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
42. Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
Schlei Z; Tan W; Faber MG; Chen H; Meagher A; Dy GK
Clin Lung Cancer; 2018 Nov; 19(6):467-475. PubMed ID: 30369425
[TBL] [Abstract][Full Text] [Related]
43. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
[TBL] [Abstract][Full Text] [Related]
44. A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer.
Dasanu CA; Wiernik PH; Vaillant J; Alexandrescu DT
Skinmed; 2007; 6(2):95-6. PubMed ID: 17366681
[TBL] [Abstract][Full Text] [Related]
45. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
[TBL] [Abstract][Full Text] [Related]
46. [Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin
in Patients with IIIa Lung Adenocarcinoma].
Zhang S; Xu P; Yuan C; Ou W
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):365-8. PubMed ID: 26104893
[TBL] [Abstract][Full Text] [Related]
47. Pemetrexed-induced skin sclerosis.
Merklen-Djafri C; Imbert E; Courouge-Dorcier D; Schott R; Méraud JP; Muller C; Tebacher M; Springinsfeld G; Cribier B; Lipsker D
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):452-3. PubMed ID: 22397832
[No Abstract] [Full Text] [Related]
48. Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm.
Noronha V; Zanwar S; Joshi A; Patil VM; Mahajan A; Janu A; Agarwal JP; Bhargava P; Kapoor A; Prabhash K
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):23-29. PubMed ID: 29239731
[TBL] [Abstract][Full Text] [Related]
49. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
50. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
51. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
[TBL] [Abstract][Full Text] [Related]
52. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy-induced inflammation of seborrheic keratoses due to pemetrexed treatment.
Matsudate Y; Murao K; Kubo Y
J Dermatol; 2017 May; 44(5):602-603. PubMed ID: 27345694
[No Abstract] [Full Text] [Related]
54. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
[TBL] [Abstract][Full Text] [Related]
55. Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma.
Ishikawa K; Sakai T; Saito-Shono T; Miyawaki M; Osoegawa A; Sugio K; Ono A; Mori H; Nishida H; Yokoyama S; Okamoto O; Fujiwara S; Hatano Y
J Dermatol; 2016 Sep; 43(9):1071-4. PubMed ID: 26992088
[TBL] [Abstract][Full Text] [Related]
56. Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
Capelle H; Tummino C; Greillier L; Gouitaa M; Birnbaum J; Ausias N; Barlesi F; Montana M
J Clin Pharm Ther; 2018 Jun; 43(3):320-326. PubMed ID: 29092096
[TBL] [Abstract][Full Text] [Related]
57. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.
Miyahara T; Sueoka-Aragane N; Iwanaga K; Ureshino N; Komiya K; Nakamura T; Nakashima C; Abe T; Matsunaga H; Kimura S
Med Oncol; 2017 Nov; 34(12):195. PubMed ID: 29124473
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
59. Severe toxicity in adult patients with lung cancer under treatment with pemetrexed: a prospective cohort study.
Vázquez C; Orlova M; Verzura MA; Minatta JN; Scibona P; Jáuregui EG; Díaz de Arce H; Pallotta MG; Belloso WH
J Chemother; 2019 Apr; 31(2):95-104. PubMed ID: 30739598
[TBL] [Abstract][Full Text] [Related]
60. [Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer].
Tummino C; Barlesi F; Tchouhadjian C; Tasei AM; Gaudy-Marqueste C; Richard MA; Astoul P
Rev Mal Respir; 2007 May; 24(5):635-8. PubMed ID: 17519817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
